Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Tamoxifen has been suggested to produce beneficial cardiovascular effects, although the mechanisms for these effects are not fully known. Moreover, although tamoxifen metabolites may exhibit 30-100 times higher potency than the parent drug, no previous study has compared the effects produced by tamoxifen and its metabolites on vascular function. Here, we assessed the vascular responses to acetylcholine and sodium nitroprusside on perfused hindquarter vascular bed of rats treated with tamoxifen or its main metabolites (N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen, and endoxifen) for 2 weeks. Plasma and whole-blood thiobarbituric acid reactive substances (TBARS) concentrations were determined using a fluorometric method. Plasma nitrite and NOx (nitrite + nitrate) concentrations were determined using an ozone-based chemiluminescence assay and Griess reaction, respectively. Treatment with tamoxifen reduced the responses to acetylcholine (pD(2) = 2.2 +/- 0.06 and 1.9 +/- 0.05 after vehicle and tamoxifen, respectively; P < 0.05), while its metabolites improved these responses (pD(2) = 2.5 +/- 0.04 after N-desmethyl-tamoxifen, 2.5 +/- 0.03 after 4-hydroxy-tamoxifen, and 2.6 +/- 0.08 after endoxifen; P < 0.01). Tamoxifen and its metabolites showed no effect on endothelial-independent responses to sodium nitroprusside (P > 0.05). While tamoxifen treatment resulted in significantly higher plasma and whole blood lipid peroxide levels (37% and 62%, respectively; both P < 0.05), its metabolites significantly decreased lipid peroxide levels (by approximately 50%; P < 0.05). While treatment with tamoxifen decreased the concentrations of markers of nitric oxide formation by approximately 50% (P < 0.05), tamoxifen metabolites had no effect on these parameters (P > 0.05). These results suggest that while tamoxifen produces detrimental effects, its metabolites produce counteracting beneficial effects on the vascular system and on nitric oxide/reactive oxygen species formation.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1742-7843.2009.00377.xDOI Listing

Publication Analysis

Top Keywords

tamoxifen metabolites
20
tamoxifen
12
005 tamoxifen
12
metabolites
9
perfused hindquarter
8
hindquarter vascular
8
vascular bed
8
responses acetylcholine
8
sodium nitroprusside
8
concentrations determined
8

Similar Publications

Endoxifen is the most active metabolite of tamoxifen and plays a central role in its therapeutic efficacy. However, significant interindividual variability in endoxifen plasma concentrations, driven by both genetic and non-genetic factors, may result in subtherapeutic exposure for a substantial subset of patients. This study evaluated the influence of CYP2D6 phenotype and age on endoxifen steady-state concentrations and explored the clinical utility of therapeutic drug monitoring (TDM) to guide tamoxifen therapy.

View Article and Find Full Text PDF

Background: Capsular contracture is a major complication of breast reconstruction with silicone implants, affecting patients' quality of life due to pain and esthetic concerns. Capsular contracture is considered to result from an excessive fibrous foreign body reaction to the implant, but its precise mechanism remains unclear, and no effective preventative approaches have been established. Previously, we reported that transdermal application of 4-hydroxytamoxifen (4-OH TAM), an active metabolite of TAM, inhibited capsule formation in a mouse model.

View Article and Find Full Text PDF

Secondary metabolites from the Zingiberaceae family are enormously active compounds used especially in traditional medicine practices and can be effective drugs in cancer treatment. 8-Isopropyl-5,11-dimethyl-dodecane-4,5-diol (Zr I) was isolated from chloroform extract of Zingiber roseum rhizome and analyzed for anticancer activity against MCF-7 breast cancer cell line. The structure was elucidated based on advanced IR, GC MS, and 2D NMR spectral data.

View Article and Find Full Text PDF

Current drug discovery is limited by the lack of single-cell data on drug uptake, metabolism, and effects, as population-level methods obscure cellular heterogeneity. While single-cell RNA sequencing has revealed drug resistance mechanisms, it cannot simultaneously measure drug concentrations and cellular responses. Raman spectroscopy probes single-cell drug effects but lacks sensitivity for drug or its metabolite quantification, whereas single-cell mass spectrometry (MS) offers high sensitivity but consumes samples, preventing repeated measurements.

View Article and Find Full Text PDF

Metabolomic Profiling Reveals Key Metabolic Alterations in MCF7 Tamoxifen-Resistant Cells Following EPAS1 Inhibition.

J Proteome Res

August 2025

Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, South Korea.

Tamoxifen (TAM) is a frontline therapy for luminal A breast cancer, yet acquired resistance poses a significant clinical challenge. This study investigates the molecular and metabolic basis of TAM resistance in MCF7/Tam1 cells, focusing on EPAS1 (HIF-2α)-driven hypoxia-induced metabolic reprogramming and the potential of the EPAS1 inhibitor PT2977 to restore TAM sensitivity. Comparative transcriptomic analysis revealed upregulation of EPAS1 along with enrichment of hypoxia-associated pathways, including JAK-STAT, TGF-beta, and lipid metabolism in resistant cells.

View Article and Find Full Text PDF